FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1608-1614 November 25, 1993 Number 22 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Interferon alfa and cytotoxic drugs have synergistic effects in patients with non-Hodgkin's lymphoma. In 1986, we designed a clinical trial to evaluate the benefit of concomitant administration of recombinant interferon alfa with a regimen containing doxorubicin in patients with follicular non-Hodgkin's lymphoma.

Methods The trial involved 242 patients with advanced low-grade follicular non-Hodgkin's lymphoma selected on the basis of clinical, radiographic, and biologic criteria. All patients were treated with a regimen consisting of cyclophosphamide, doxorubicin, teniposide, and prednisone (CHVP), given monthly for six cycles and then every two months for one year. After randomization, 123 patients also received interferon alfa-2b at a dosage of 5 million units three times weekly for 18 months. The remaining 119 patients received chemotherapy alone.

Results As compared with the patients treated with CHVP only, the patients treated with CHVP plus interferon alfa had a higher overall rate of response (85 percent vs. 69 percent, P = 0.006), a longer median event-free survival (34 months vs. 19 months, P<0.001), and a higher rate of survival at 3 years (86 percent vs. 69 percent, P = 0.02). Granulocyte toxicity was greater in the patients treated with CHVP plus interferon alfa than in those treated with CHVP alone. There were no treatment-related deaths. Interferon alfa had to be stopped because of toxic effects (fatigue and hepatitis) in 13 patients (11 percent).

Conclusions The addition of interferon alfa to a regimen containing doxorubicin increased the rate of response, event-free survival, and overall survival in patients with advanced follicular non-Hodgkin's lymphoma, without serious toxicity, although some patients were unable to tolerate the side effects.

Source Information

From the Departments of Hematology (P.S.-C., P.B., C.G.) and Biostatistics and Medical Information Systems (E.L.), Hopital Saint-Louis, Paris; the Department of Pathology, Hopital Necker, Paris (N.B., M.P.); Hopital Henri Mondor, Creteil, France (F.R., C.H.); Centre Hospitalo-Universitaire de Caen, Caen, France (M.L.); Universite Catholique de Louvain, Louvain, Belgium (A.B.); Centre Hospitalier Lyon-Sud, Pierre Benite, France (B.C.); and Schering-Plough, Levallois, France (Y.P.).

Address reprint requests to Dr. Solal-Celigny at Centre Hayem, Hopital Saint-Louis, 1 Ave. Cl. Vellefaux, 75010 Paris, France.

Full Text of this Article

This article has been cited by other articles:

• Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d'Amore, F., Diaz, M. G., Petrini, M., Sebban, C., Zinzani, P. L., van Oers, M. H.J., van Putten, W., Bischof-Delaloye, A., Rohatiner, A., Salles, G., Kuhlmann, J., Hagenbeek, A. (2008). Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. JCO 26: 5156-5164 [Abstract] [Full Text]  
• Sebban, C., Brice, P., Delarue, R., Haioun, C., Souleau, B., Mounier, N., Brousse, N., Feugier, P., Tilly, H., Solal-Celigny, P., Coiffier, B. (2008). Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study. JCO 26: 3614-3620 [Abstract] [Full Text]  
• Portlock, C. S., Hamlin, P., Noy, A., Chey, W., Gaydos, C. A., Palomba, L., Schwartz, I., Corcoran, S., Rosenzweig, L., Walker, D., Papanicolaou, G., Markowitz, A. (2008). Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. Ann Oncol 19: 254-258 [Abstract] [Full Text]  
• van Oers, M. H. J., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., van't Veer, M., Vranovsky, A., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C., Hagenbeek, A. (2006). Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108: 3295-3301 [Abstract] [Full Text]  
• Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P., Haioun, C., Tilly, H., Feugier, P., Bouabdallah, R., Doyen, C., Salles, G., Coiffier, B. (2006). Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108: 2540-2544 [Abstract] [Full Text]  
• Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M., Miller, T. P. (2005). New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. JCO 23: 8447-8452 [Abstract] [Full Text]  
• Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P., Cornillet-LeFebvre, P., Escoffre-Barbe, M., Maisonneuve, H., Delwail, V., Gressin, R., Legouffe, E., Vilque, J.-P., Desablens, B., Jaubert, J., Ramee, J.-F., Jenabian, A., Thyss, A., Le Pourhiet-Le Mevel, A., Travade, P., Delepine, R., Colombat, P., GOELAMS, (2005). High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105: 3817-3823 [Abstract] [Full Text]  
• Rohatiner, A.Z.S., Gregory, W.M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., Fisher, R.I., Unterhalt, M., Arranz, R., Chisesi, T., Aviles, A., Lister, T.A. (2005). Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma. JCO 23: 2215-2223 [Abstract] [Full Text]  
• Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A., Smith, P. (2005). CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417-1423 [Abstract] [Full Text]  
• Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., Wahl, R. L. (2005). 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. NEJM 352: 441-449 [Abstract] [Full Text]  
• Vallisa, D., Bernuzzi, P., Arcaini, L., Sacchi, S., Callea, V., Marasca, R., Lazzaro, A., Trabacchi, E., Anselmi, E., Arcari, A. L., Moroni, C., Berte, R., Lazzarino, M., Cavanna, L. (2005). Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience. JCO 23: 468-473 [Abstract] [Full Text]  
• Belhadj, K., Delfau-Larue, M.-H., Elgnaoui, T., Beaujean, F., Beaumont, J.-L., Pautas, C., Gaillard, I., Kirova, Y., Allain, A., Gaulard, P., Farcet, J.-P., Reyes, F., Haioun, C. (2004). Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 15: 504-510 [Abstract] [Full Text]  
• Lister, T. A. (2003). High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?. JCO 21: 3894-3896 [Full Text]  
• Fernandez-Ruiz, E., Cabrerizo, M., Ortega, M., Blas, C., Llamas, P., Santos-Roncero, M., Nieto, S., Acevedo, A., Perez, G., Nicolas, C., Fernandez-Ranada, J. M., Arranz, R. (2003). High Molecular Response Rate and Clinical Correlation in Patients with Follicular Lymphoma Treated with Cyclophosphamide-Vincristine-Prednisone plus Interferon {alpha} 2b. Clin. Cancer Res. 9: 2497-2503 [Abstract] [Full Text]  
• Damaj, G., Verkarre, V., Delmer, A., Solal-Celigny, P., Yakoub-Agha, I., Cellier, C., Maurschhauser, F., Bouabdallah, R., Leblond, V., Lefrere, F., Bouscary, D., Audouin, J., Coiffier, B., Varet, B., Molina, T., Brousse, N., Hermine, O. (2003). Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol 14: 623-629 [Abstract] [Full Text]  
• Peterson, B. A., Petroni, G. R., Frizzera, G., Barcos, M., Bloomfield, C. D., Nissen, N. I., Hurd, D. D., Henderson, E. S., Sartiano, G. P., Johnson, J. L., Holland, J. F., Gottlieb, A. J. (2003). Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B. JCO 21: 5-15 [Abstract] [Full Text]  
• Klasa, R. J., Meyer, R. M., Shustik, C., Sawka, C. A., Smith, A., Guevin, R., Maksymiuk, A., Rubinger, M., Samosh, M., Laplante, S., Grenier, J.-F. (2002). Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin's Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. JCO 20: 4649-4654 [Abstract] [Full Text]  
• Dillman, R. O. (2002). Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma. JCO 20: 3545-3557 [Full Text]  
• Talpaz, M., O'Brien, S., Rose, E., Gupta, S., Shan, J., Cortes, J., Giles, F. J., Faderl, S., Kantarjian, H. M. (2001). Phase 1 study of polyethylene glycol formulation of interferon {alpha}-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 98: 1708-1713 [Abstract] [Full Text]  
• Mandigers, C. M. P. W., Meijerink, J. P. P., Mensink, E. J. B. M., Tonnissen, E. L. R. T. M., Hebeda, K. M., Bogman, M. J. J. T., Raemaekers, J. M. M. (2001). Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 98: 940-944 [Abstract] [Full Text]  
• Gutierrez, M., Chabner, B. A., Pearson, D., Steinberg, S. M., Jaffe, E. S., Cheson, B. D., Fojo, A., Wilson, W. H. (2000). Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH. JCO 18: 3633-3642 [Abstract] [Full Text]  
• Cheson, B. D. (2000). The Curious Case of the Baffling Biological. JCO 18: 2007-2009 [Full Text]  
• Fisher, R. I., Dana, B. W., LeBlanc, M., Kjeldsberg, C., Forman, J. D., Unger, J. M., Balcerzak, S. P., Gaynor, E. R., Roy, V., Miller, T. (2000). Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin's Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809. JCO 18: 2010-2016 [Abstract] [Full Text]  
• Mounter, P J, Lennard, A L (1999). Classic diseases revisited: Management of non-Hodgkin's lymphomas. Postgrad. Med. J. 75: 2-6 [Abstract] [Full Text]  
• Wadler, S., Schwartz, E. L. (1997). New Advances in Interferon Therapy of Cancer. The Oncologist 2: 254-267 [Abstract] [Full Text]  
• Schmidt, W., Buschle, M., Zauner, W., Kirlappos, H., Mechtler, K., Trska, B., Birnstiel, M. L. (1997). Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl. Acad. Sci. USA 94: 3262-3267 [Abstract] [Full Text]